Abstract:Cardiovascular diseases (CVDs) are complex, multifactorial conditions that require personalized assessment and treatment. Advancements in multi-omics technologies, namely RNA sequencing and whole-genome sequencing, have provided translational researchers with a comprehensive view of the human genome. The efficient synthesis and analysis of this data through integrated approach that characterizes genetic variants alongside expression patterns linked to emerging phenotypes, can reveal novel biomarkers and enable the segmentation of patient populations based on personalized risk factors. In this study, we present a cutting-edge methodology rooted in the integration of traditional bioinformatics, classical statistics, and multimodal machine learning techniques. Our approach has the potential to uncover the intricate mechanisms underlying CVD, enabling patient-specific risk and response profiling. We sourced transcriptomic expression data and single nucleotide polymorphisms (SNPs) from both CVD patients and healthy controls. By integrating these multi-omics datasets with clinical demographic information, we generated patient-specific profiles. Utilizing a robust feature selection approach, we identified a signature of 27 transcriptomic features and SNPs that are effective predictors of CVD. Differential expression analysis, combined with minimum redundancy maximum relevance feature selection, highlighted biomarkers that explain the disease phenotype. This approach prioritizes both biological relevance and efficiency in machine learning. We employed Combination Annotation Dependent Depletion scores and allele frequencies to identify variants with pathogenic characteristics in CVD patients. Classification models trained on this signature demonstrated high-accuracy predictions for CVD. The best performing of these models was an XGBoost classifier optimized via Bayesian hyperparameter tuning, which was able to correctly classify all patients in our test dataset. Using SHapley Additive exPlanations, we created risk assessments for patients, offering further contextualization of these predictions in a clinical setting. Across the cohort, RPL36AP37 and HBA1 were scored as the most important biomarkers for predicting CVDs. A comprehensive literature review revealed that a substantial portion of the diagnostic biomarkers identified have previously been associated with CVD. The framework we propose in this study is unbiased and generalizable to other diseases and disorders.

Leveraging epitranscriptomics for cardiovascular disease theranostics

The clinical value of quantitative cardiovascular molecular imaging: a step towards precision medicine

Dawn of Epitranscriptomic Medicine

Exosomes and Their Derivatives As Biomarkers and Therapeutic Delivery Agents for Cardiovascular Diseases: Situations and Challenges.

Translational applications of molecular imaging in cardiovascular disease and stem cell therapy

Novel cutting edge nano-strategies to address old long-standing complications in cardiovascular diseases. A comprehensive review

Multimodal AI/ML for discovering novel biomarkers and predicting disease using multi-omics profiles of patients with cardiovascular diseases

Translational and emerging clinical applications of metabolomics in cardiovascular disease diagnosis and treatment

[Cardiovascular proteomics: challenges and opportunities for cardiologists of the future]

Closer to the Heart: Harnessing the Power of Targeted Extracellular Vesicle Therapies.

A Translational Framework of Genoproteomic Studies for Cardiovascular Drug Discovery

Single chain fragment variable, a new theranostic approach for cardiovascular diseases

Bioinformatic platforms for clinical stratification of natural history of atherosclerotic cardiovascular diseases

The diagnostic and prognostic potential of plasma extracellular vesicles for cardiovascular disease.

In Vivo Cardiovascular Molecular Imaging: Contributions to Precision Medicine and Drug Development

Translating metabolic and cardiovascular research into effective treatments: What's next?

Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases

Computational approaches identify a transcriptomic fingerprint of drug-induced structural cardiotoxicity

Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment

Perspectives on the success of plasma lipidomics in cardiovascular drug discovery and future challenges

Clinical Perspectives in Epitranscriptomics